Capricor Therapeutics, Inc. (CAPR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Capricor Therapeutics, Inc. (CAPR) closed at USD 6.59 on 2026-10-14, a change of +6.6 % over the past year, with a market capitalization of USD 422.67M.

Capricor Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Capricor Therapeutics, Inc. key figures

Previous close

USD 6.59 (2026-10-14)

1-year change

+6.6 %

Market cap

USD 422.67M

Enterprise value

USD 275.78M

P/E ratio (trailing)

-2.82

P/E ratio (forward)

-5.01

EPS (trailing)

-2.58

EPS (forward)

-1.45

PEG ratio

0.38

Price to book

1.72

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.84

Employees

231

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Capricor Therapeutics, Inc. and compare it with other stocks.